Section Arrow
Quote
COEP.NASDAQ
- Coeptis Therapeutics Holdings Inc
Quotes are at least 15-min delayed:2025/07/22 19:14 EDT
After Hours
Last
 10.98
+0.07 (+0.64%)
Bid
10.39
Ask
10.99
High 11 
Low 10.2 
Volume 57 
Regular Hours
Last
 10.91
+0.21 (+1.96%)
Day High 
10.99 
Prev. Close
10.7 
1-M High
11.7 
Volume 
68.15K 
Bid
10.39
Ask
10.99
Day Low
10 
Open
10.775 
1-M Low
6.91 
Market Cap 
37.60M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.85 
20-SMA 8.76 
50-SMA 9 
52-W High 13.7 
52-W Low 2.31 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.13/-0.29
Enterprise Value
37.77M
Balance Sheet
Book Value Per Share
1.84
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.053+0.002+3.92%-- 
After Hours 0.0527 -0.0003 -0.57%
PLRZPolyrizon Ltd1.45+0.5422+59.73%-- 
After Hours 1.8899 +0.4399 +30.34%
REPLReplimune Group2.805-9.52-77.24%-- 
After Hours 2.7905 -0.0145 -0.52%
IOVAIovance Biotherapeutics3.13+0.64+25.70%-- 
After Hours 3.2 +0.07 +2.24%
TNFATNF Pharmaceuticals Inc.0.107-0.0224-17.31%-- 
After Hours 0.1068 -0.0002 -0.19%
Quotes are at least 15-min delayed：2025/07/22 19:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.